[go: up one dir, main page]

WO2012066565A3 - Asenapine maleate amorphous and crystalline form and process for preparation thereof - Google Patents

Asenapine maleate amorphous and crystalline form and process for preparation thereof Download PDF

Info

Publication number
WO2012066565A3
WO2012066565A3 PCT/IN2011/000783 IN2011000783W WO2012066565A3 WO 2012066565 A3 WO2012066565 A3 WO 2012066565A3 IN 2011000783 W IN2011000783 W IN 2011000783W WO 2012066565 A3 WO2012066565 A3 WO 2012066565A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
crystalline form
asenapine maleate
amorphous
maleate amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000783
Other languages
French (fr)
Other versions
WO2012066565A2 (en
Inventor
Shriprakash Dhar Dwivedi
Ashok Prasad
Piyush Rajendra Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2012066565A2 publication Critical patent/WO2012066565A2/en
Publication of WO2012066565A3 publication Critical patent/WO2012066565A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention discloses substantially pure monoclinic form of asenapine maleate having d95 particle size of less than about 100 microns.
PCT/IN2011/000783 2010-11-16 2011-11-11 Asenapine maleate amorphous and crystalline form and process for preparation thereof Ceased WO2012066565A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3133/MUM/2010 2010-11-16
IN3133MU2010 2010-11-16

Publications (2)

Publication Number Publication Date
WO2012066565A2 WO2012066565A2 (en) 2012-05-24
WO2012066565A3 true WO2012066565A3 (en) 2012-07-26

Family

ID=45607321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000783 Ceased WO2012066565A2 (en) 2010-11-16 2011-11-11 Asenapine maleate amorphous and crystalline form and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2012066565A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709616B1 (en) * 2011-05-18 2018-01-24 Laboratorios Lesvi, S.L. Synthesis of a stable micronised monoclinic form of asenapine maleate
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
PT2878299T (en) * 2012-07-26 2018-07-06 Hisamitsu Pharmaceutical Co Adhesive patch
CN104447771A (en) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 Stable asenapine maleate sublingual compound
CN103772402A (en) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 Novel refining method of asenapine maleate crude product
EP3307245A1 (en) 2015-06-11 2018-04-18 Alrise Biosystems GmbH Process for the preparation of drug loaded microparticles
PL3338768T3 (en) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
ES3001152T3 (en) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN118806732A (en) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 Transdermal therapeutic system containing asenapine
KR102802121B1 (en) 2018-06-20 2025-05-02 에르테에스 로만 테라피-시스테메 아게 Transdermal therapeutic system containing asenapine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106135A1 (en) * 2005-04-07 2006-10-12 N.V. Organon Crystal form of asenapine maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (en) 1976-05-24 1977-11-28 Akzo Nv NEW TETRACYCLICAL DERIVATIVES.
ATE167057T1 (en) 1994-03-02 1998-06-15 Akzo Nobel Nv SUBLINGUAL OR BUCCAL MEDICINAL PRODUCT
DE102004009217A1 (en) 2004-02-12 2005-09-01 Gühring, Jörg, Dr. Clamping element for tool clamps
CL2007002891A1 (en) 2006-10-06 2008-04-18 Organon Nv TRANS-5-CHLORINE-2-METHYL-2,3,3A, 12B-TETRAHIDRO-1H-DIBENZ- [2,3: 6,7] OXEPINO [4,5-C] PIRROL 50% AMORFO BASED ON TOTAL WEIGHT OF THE COMPOUND; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF A SELECTED DISORDER BETWEEN E

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106135A1 (en) * 2005-04-07 2006-10-12 N.V. Organon Crystal form of asenapine maleate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUNKE C W ET AL: "PHYSICO-CHEMICAL PROPERTIES AND STABILITY OF TRANS-5-CHLORO-2- METHYL-2,3,3A, 12B-TETRAHYDRO-1H-DIBENZ-2,3:6,70 OXEPINO-4,5-C) PYRROLIDINE MALEATE", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 40, no. 5, 1 May 1990 (1990-05-01), pages 536 - 539, XP000561359, ISSN: 0004-4172 *

Also Published As

Publication number Publication date
WO2012066565A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2012066565A3 (en) Asenapine maleate amorphous and crystalline form and process for preparation thereof
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2011138281A3 (en) Process for the preparation of dithiine tetracarboxydiimides
WO2011106478A3 (en) Apixaban formulations
WO2009114601A3 (en) Preparation of lenalidomide
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2011107186A3 (en) Compounds for electronic devices
EP2649621A4 (en) Stable dispersions of monocrystalline nanometric silver particles
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
ZA201202387B (en) Particulate composition containing anhtdrous crystalline of 2-o-a-d-glucosyl-l-ascorbic acid,process for producing the same, and uses thereof
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
EP2240477B8 (en) Novel process for the preparation of scopine esters
WO2010059913A3 (en) Preparation of rasagiline and salts thereof
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2012085927A3 (en) Tadalafil compositions
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2012035283A8 (en) Pharmaceutical composition
EP2216333A3 (en) Crystalline forms of Dexlansoprazole
WO2012025828A3 (en) Superfine powdered stevia
WO2012053011A3 (en) Ophthalmic compositions comprising brinzolamide
WO2011146838A3 (en) Process for making titanium compounds
WO2011052940A3 (en) Process for preparing clopidogrel hydrogensulfate form i
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
WO2011100282A3 (en) Imatinib mesylate polymorphs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11817536

Country of ref document: EP

Kind code of ref document: A2